Sight Sciences Q2 revenue falls 8% but beats estimates
Overview
Sight Sciences Q2 revenue falls 8% yr/yr but beats analyst expectations, per LSEG data
Operating expenses decreased 9% yr/yr
Company raises full-year revenue guidance, indicating confidence in future performance
Outlook
Sight Sciences raises full-year 2025 revenue guidance to $72.0 mln-$76.0 mln
Company reaffirms 2025 adjusted operating expenses guidance at $101.0 mln-$105.0 mln
Sight Sciences expects tariff costs to decrease to $1.0 mln-$1.5 mln in 2025
Company anticipates 5%-10% revenue decline for full-year 2025 compared to 2024
Result Drivers
MEDICARE RESTRICTIONS - Decline in Surgical Glaucoma revenue attributed to Medicare coverage restrictions on MIGS procedures with cataract surgery
ORDERING ACCOUNTS - Increase in Surgical Glaucoma ordering accounts to an all-time high, partially offsetting revenue decline
DRY EYE FOCUS - Decrease in Dry Eye revenue due to focus on achieving reimbursed market access for TearCare procedures
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $19.60 mln | $18.20 mln (6 Analysts) |
Q2 Net Income | -$11.90 mln | ||
Q2 Gross Margin | 85.0% | ||
Q2 Gross Profit | $16.60 mln | ||
Q2 Operating Expenses | $28.30 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Sight Sciences Inc is $4.00, about 8% above its August 6 closing price of $3.68
Press Release:
